GET DAILY SIGNALSChampions Oncology (CSBR): Insights into Its Oncology Research Services Business
Key Takeaways
- Champions Oncology, Inc. (CSBR) is a technology-enabled oncology research services company headquartered in Hackensack, New Jersey.
- The company helps pharmaceutical and biotechnology firms advance cancer drug discovery and development through its proprietary TumorGraft (patient-derived xenograft) platform and translational research services.
- Its business operates primarily through one segment — oncology services — with revenue generated mainly from research services and, more recently, data licensing.
- Champions Oncology also develops Lumin Bioinformatics, an oncology data and analytics software platform, and operates a wholly owned therapeutic subsidiary called Corellia.
- The company is a small-cap healthcare business with a customer base concentrated among biopharma organizations, which makes it sensitive to industry funding cycles.
Introduction
CSBR represents the Nasdaq listing for Champions Oncology, Inc., a firm positioned at the crossroads of oncology research and technology. Instead of pursuing its own drug development like many traditional biotechs, the company functions mainly as a research partner. It provides models, data, and services that help pharmaceutical and biotechnology companies test and refine experimental cancer therapies ahead of and during clinical trials. This setup offers investors exposure to oncology drug development with a lower binary risk profile compared to single-candidate drug plays.
Company Background and Operations
Champions Oncology traces its roots to 1985 and previously operated under the name Champions Biotechnology before rebranding in April 2011. Headquartered in Hackensack, New Jersey, the firm reports on a fiscal year ending in April and focuses on a single reportable segment: oncology services.
At the heart of its model sits the TumorGraft Technology Platform, which implants human tumor tissue into immune-deficient mice to generate patient-derived xenograft (PDX) models. These models retain much of the original tumor's biology, offering useful insights into how therapies might perform in humans. The company maintains one of the larger collections of clinically relevant PDX and primary hematological malignancy models available.
This foundation supports Translational Oncology Solutions (TOS), a suite of research services that assist biopharma clients with studies, data generation, and performance predictions for therapies. Revenue primarily stems from these predictive modeling efforts. The company also licenses data via Lumin Bioinformatics, its analytics platform built from research and clinical findings, while its wholly owned subsidiary Corellia targets discovery and development work.
Revenue Streams and Competitive Position
Most revenue comes from oncology research services sold to pharmaceutical and biotechnology companies, supplemented by more variable data licensing deals. The client base remains concentrated in biopharma, with marketing handled through direct sales and online channels.
In the contract research space, Champions Oncology competes with various preclinical and clinical organizations as well as internal teams at larger developers. Its edge comes from the scale and clinical relevance of its tumor model bank plus the proprietary data it generates. As artificial intelligence and machine learning gain traction in development decisions, management notes that richly annotated, patient-derived data remains a valuable and limited resource.
Why Investors Track CSBR
Several longer-term traits draw attention to CSBR. The services-oriented approach can produce steadier revenue through study contracts, unlike the milestone-heavy economics common in pure drug development. Its data platform and model collection form a differentiated asset that may grow in value as biopharma leans more on data-driven and AI-supported methods. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Financially, recent periods show improving gross margins, positive adjusted EBITDA, and a debt-free balance sheet. These elements appeal when assessing progress toward sustainable profitability. Potential growth areas include sales team expansion, bringing certain lab capabilities in-house such as radiopharmaceutical work, and scaling the data-licensing side.
Important Risks to Weigh
Several factors merit consideration with CSBR. As a small-cap name, its concentrated biopharma customer base ties performance closely to industry funding cycles and broader economic conditions. A dip in biotech financing or development spending can quickly soften demand for services.
Quarterly revenue can fluctuate, especially around data-licensing contracts that close on irregular schedules; management advises viewing those on an annual basis. GAAP net losses have appeared even alongside positive adjusted EBITDA due to non-cash items and investments in growth areas like the data platform, sales expansion, and Corellia. Competition from larger, better-funded players persists, and the technology platform represents just one of several approaches in oncology research.
Enhancing Analysis with Tickeron Tools
When evaluating stocks like this one, I find Tickeron's AI Screener helpful for quickly filtering opportunities based on technical indicators, fundamentals, and industry patterns. It allows me to compare CSBR against peers and refine my own research workflow without starting from scratch each time.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CSBR's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for CSBR turned positive on October 27, 2026. Looking at past instances where CSBR's MACD turned positive, the stock continued to rise in 38 of 49 cases over the following month. The odds of a continued upward trend are 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 68 cases where CSBR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on CSBR as a result. In 89 of 116 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
Following a +2.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where CSBR advanced for three days, in 161 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
CSBR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CSBR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for CSBR entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.269) is normal, around the industry mean (3.498). P/E Ratio (-60.375) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (4.510) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.136) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. CSBR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CSBR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of advanced technology solutions and services for oncology drugs
Industry Biotechnology
Advertisement